Show simple item record

AuthorAl-Amleh, Esraa K.
AuthorAl-Sanabra, Ola M.
AuthorAlqaisi, Khalid M.
AuthorAlqaraleh, Moath
AuthorAl-Nahal, Jumana
AuthorHamadneh, Lama
AuthorMalki, Mohammed Imad
AuthorAlhmoud, Jehad F.
Available date2022-09-08T05:19:12Z
Publication Date2022-08-24
Publication NameJCM
Identifierhttp://dx.doi.org/10.3390/jcm11174954
CitationAl-Amleh, E.K.; Al-Sanabra, O.M.; Alqaisi, K.M.; Alqaraleh, M.; Al-Nahal, J.; Hamadneh, L.; Malki, M.I.; Alhmoud, J.F. Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients. J. Clin. Med. 2022, 11, 4954. https://doi.org/10.3390/jcm11174954
URIhttp://hdl.handle.net/10576/33767
Abstract(1) Background: Chronic myeloid leukemia is defined as the neoplastic development of mostly myeloid cells in the bone marrow. Several treatments, including chemotherapy, radiation, hormone treatment, and immunological therapy, can be used to control this condition. The therapeutic impact on leukemic individuals varies, and the response to therapy varies between patients due to disease heterogeneity. The primary goal of this study is to compare the effects of single and Imatinib (IM) and Hydroxyurea (HU) combined treatment on hematological parameters and gene expression in CML patients. (2) Methods: This study was conducted on 51 patients, with chronic myeloid leukemia, who were admitted to Al-Basher hospital in Amman, Jordan, for follow-up. Their hematological parameters were checked and gene expression was measured for (BCL2, PP2A, CIP2A, and WT1). (3) Results: The BCL2 gene was found to be less expressed in both IM and (HU + IM) treatments as compared to the HU group alone, while PP2A gene expression was raised. Such a thing indicates that the outcome of the combined therapy method is not ideal, since PP2A activation causes CML cells to move toward the blast crisis stage. Furthermore, CIP2A gene expression revealed that IM and (HU + IM) had the same therapeutic effect and were more successful in CML patients than HU alone. With regards to the treatment effect on hematological parameters, notably in CML patients in later stages, the combination therapy (HU + IM) raised lymphocyte count, indicating a greater response to the treatment. When compared to single medicines, the combination treatment reduced the proportion of neutrophils to normal reference ranges. Platelet counts, on the other hand, dramatically decreased in both IM and (HU + IM). (4) Conclusion: Because the studied genes (BCL2, PP2A, CIP2A, and WT1) are participating in cell proliferation and death, the findings show that the examined genes are significant to understand the efficacy of various therapies. Furthermore, it was found that there was a clear effect of the clinic-based strategic treatment on hematological indicators such as WBCs, lymphocytes, neutrophils, and platelet counts.
SponsorFinancial support was offered by Al-Ahliyya Amman University/Jordan. Open Access funding provided by the Qatar National Library (QNL).
Languageen
PublisherMDPI
SubjectBCL2
CIP2A
CML
gene expression
hydroxyurea
imatinib
leukemia
PP2A
WT1
TitleInvestigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
TypeArticle
Issue Number17
Volume Number11
ESSN2077-0383
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record